| Gao Jing,Hu Jiyi,Yang Jing,et al.Primary results of proton radiotherapy for 26 meningioma patients[J].Chinese Journal of Radiological Medicine and Protection,2020,40(4):302-307 |
| Primary results of proton radiotherapy for 26 meningioma patients |
| Received:June 07, 2019 |
| DOI：10.3760/cma.j.issn.0254-5098.2020.04.010 |
| KeyWords:Proton therapy Meningioma Toxicities Efficacy |
| FundProject: |
| Author Name | Affiliation | E-mail | | Gao Jing | Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201315, China | | | Hu Jiyi | Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201315, China | | | Yang Jing | Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201315, China | | | Qiu Xianxin | Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201315, China | | | Hu Weixu | Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201315, China | | | Lu Jiade | Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201315, China | | | Kong Lin | Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201315, China | Konglinjiang@163.com |
|
| Hits: 5352 |
| Download times: 2170 |
| Abstract:: |
| Objective To investigate the safety and efficacy of proton beam radiation therapy (PBRT) in patients with World Health Organization (WHO) GradeⅠ/Ⅱ meningioma. Methods Twenty-six patients with intracranial (n=8, 30.8%) or skull-base (n=18, 69.2%) meningioma treated with PBRT from May 2015 to October 2018 were analyzed retrospectively. The median age of the cohort was 42 years (range 15-79 years). Eight patients had WHO Grade Ⅰ meningioma, and 9 had WHO Grade Ⅱ meningioma, respectively. Nine patients had clinical (radiological) diagnosis without histology. Seven patients received post-surgical PBRT (2 patients underwent Simpson Ⅰ-Ⅲ resection,5 patients underwent Simpson Ⅳ-Ⅴ resection); 10 patients were irradiated for local recurrence after initial surgical resection. Results All patients completed planned PBRT without break, and the median dose was 54 Gray-Equivalent (GyE) (range 50.4-60 GyE, 1.8-2 GyE/daily fraction). With a median follow-up of 22.2 (range 1.6-36.4) months, the 2-year overall survival and progression-free survival rates were both 100%. Grade Ⅰ skin erythema and alopecia were observed in 22 patients and Grade Ⅰ mucositis was observed in 2 patients. No acute of late toxicities of Grade 2 or above was observed. Conclusions PBRT appeared to be a favorable treatment option for intracranial and skull base meningioma. Treatment-induced adverse effects and early response to PBRT were both highly acceptable. Longer follow-up is needed to evaluate the long-term outcome in terms of disease control, survival, as well as potential late effects. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
